Thank everyone. afternoon, you very much, Taylor, and good
our upon is alone. $XXX markets in million blood other therapy mortality today, million press human deadly EU-approved using our These sales purification core XXX,XXX including and everyday discussed sepsis, standard care conditions. is months in more than built I release are date, by in our despite and ICU more earnings complication critical respiratory where XX than inflammation CytoSorb $XX.X multibillion-dollar and cardiac trauma, flagship last XX to countries high As business CytoSorb life-threatening treating conditions with the in failure, common worldwide injury, addresses in to liver failure burn therapies. surgery like surgery treatments
patients perioperative in undergoing blood of trial reduction to surgery that ticagrelor. known a increasingly the has U.S. and with With our illness, our the more receiving system is life-saving Brilinta, choice demonstrate designed is having in and suffering focus, disasters bleeding -- also patients STAR-T DrugSorb-ATR pivotal relevant. Canadian cardiothoracic completed cardiac stent. believe the or a super antithrombotic of pandemic world a war, heart aftermath removal natural struggling as focus aspirin thinner from attack we other for is on the therapy in never our Brilinta was been the The
end. year pivotal this our STAR-T approval. year user this and countries year report versus these of FDA of X made We to so Kathy trial currently pleased in open Canadian session U.S. which lock is The where Canada a sales these both are discuss enough topics at data, for more Health on and product but to a the year-end. growth ago and rapid expect in goal Q&A the and in will an programs adoption analysis strong reflecting for database time alone provide leave up to FDA and blinded that the near we excellent we've on commentary $XXX market demand, the this before these progress detail total regulatory and breakthrough It believe XX% to As today remain QX addressable data million brief are specifically designation. of far U.S. support team estimated would with and
over recent like I'd go operating progress. to our Now
analysis. pivotal we undergoing registry surgery CABG in trial following days nearing Brilinta First, follow-up. the the is CABG of trial patient with bleeding of rates and discontinuing X last The of The STAR blinded lock perioperative STAR-T international completed low database before CytoSorb expected analysis first completion isolated data the August remains with and the highlighted related with in year-end. second in patients
expanded country ANVISA Latin also in Brazil, to America's seventh date exceeded to medical populous the the our market treatments most CytoSorb treat of worldwide We XXX,XXX shock device cumulative across world. largest XX registration and in is countries human has and which
how We solid last also are a aware not Chief helping use as and improve of her least, ECOS-XXXCY like the next inflammation organ shape that here. to improved present would the but Brilinta, the CytoSorb by cover When And transplant reducing we Kathleen donated transplant organs during highlighted trial thought of STAR-T investors, to that strategy outcomes. and Bloch full-time are I Officer. role of case potentially quality organ future perfusion, many Financial to resumes not of the quantity talk ex-vivo I'd update. pivotal to we so
patients emergency XX% patient, over you Brilinta patients go like into to the aspirin on this you in something dual get see a when If super lab antiplatelet go typically they attack. do. graphics, These the see In a having aspirin can get typically hunched called the room, and therapy. stent, they to man ultimately loaded cath a of heart which can a
cost board, wait surgery due or step-down $X,XXX patients about ward complications intensive however, approximately However, If on therapy monitor expressive a to typically at wait stent ischemia pain chest to heart approximately day cardiovascular and day patients intensive $X,XXX the the $X,XXX a widespread care cardiac and X day they at and will patients go thinners is in X% a the unit Then $XX,XXX to and from to definitive ICU step-down intensive unit bed, of and care in surgery, procedure. they for of need wait a $X,XXX these drug. a or care typically a The for eligible costing then X they in hospital disease, bleed. with where on wash and ultimately today these open blood to hospital, out and get only $X,XXX are to the anywhere just the to a unit go the in even intractable not stent. to days in ultimately will because putting wait to XX% they often surgery a these
waiting definitive surgery. surgery that actually actually need get removing the DrugSorb-ATR for or proposition this drug period without value patients to Our complications is to and while from bleeding reducing during they actively delay the blood by entire bypass preventing
with The of the the parties database STAR-T the unknown. Canada. XX STAR-T be all patients is and lock final blinded not The completion until United we study So completed lock to database The statistical and follow. centers the know? after in when nearing follow-up remained trial trial, are do analysis will study unblinded results States of data was currently at occur. STAR-T to will in in August what Data terms XXX% of on with monitoring
with reviews, will take issues DSMB lock. scheduled monitoring As device-related patients. data noted last after safety data the The one previously, place database safety the there analysis raised XX first DrugSorb-ATR board no were in at X final
Remember, serious DrugSorb-ATR STAR-T intend U.S. designation, Canada our registry With approval data, bleeding announce STAR-T breakthrough our marketing early by and regulatory CytoSorb support with initial complete early potential perioperative a expect FDA in the we faster and Health FDA the results data whether submit targeting potential for Meanwhile, of to or this late indication. review an for approval FDA STAR analysis can approval European ass initial low results our believe in the rates XXXX. to We the an before equivalent approved supportive demonstrate U.S. FDA from technology thereafter. is for with which we 'XX with this uses year-end, goal to from to again, XXXX CytoSorb, polymer is to used device the encouraging marketing indication of International Union.
successful the Europe. States, and the value in seeing United with to we continue surgeons already as CytoSorb cardiac Canada that things we're with proposition discussions have and abroad, in many potential could DrugSorb-ATR For validate that
Some bleeding of to delay get ability with patients, of include benefits and definitive complications. without low safely risk the surgery for these potential
We solved surgeons, from be we on. postoperative also time-consuming and the new potentially thinners. in For costly the to complications ICU, surgical bleeding allowing for still intraoperative operated relieve could to could recovering log reduce patients and need And blood the also scheduling due we bleeding jam due nightmare patients the surgery. cardiothoracic to of re-exploration
on where can, For to $XX,XXX wash X wait. the potential anywhere out from X depending to or reduce eliminate hospitals, we waiting to period day $X,XXX that to again, cost have Brilinta they the
hospitals a patient quality The want. reducing rating STAR this, can which also hospital. is top bleeding like And quality all help rating by be revenue, on helping operative based surgeries have to We and the relieve defined room Medicare times to for the the the could potential who CMS to time bleeding. hospital's in events criteria, table. helps by what due which adverse extra ICU more differentiate drive of for patients we more $X,XXX longer than the bleed, XX serious revenue-generating also STAR may improve also every to We on as operating objective procedural on traffic themselves or Medicaid of reduce logjam minutes of allowing costs, hospitals
is So win-win-win. of this the be one a can potential believe why we DrugSorb-ATR reasons
we designation What purification term most is dialysis proud Europe. Turning from dimension we but to which to to complementary are different CytoSorb, technology, the trademark equate that exactly now blood expanding for with people purification received say mean? the CytoSorb of in technology. blood fundamentally does have that
range to waste broad water et produces. toxins body Dialysis cetera, remove soluble different substances, small because remove products, the works we're remove that metabolic we not However, like well. the kidney that dissimilar does a molecules of dialysis and
liver works which fast that you deadly second detoxification have because and mediators, this, organ you of is of your drugs. peptides we molecules blood capable soluble It is major substances, are body, fat-soluble of aware replace. people. And removing a large well is bacterial to CytoSorb as really things However, that and liver. your inflammatory what conditions like And millions that to in target toxins, are proteins cytokines, as able toxins, afflict
the uncontrolled blood unit. massive that the of to cardiac thinners with in targeting in surgery the remove in in On organ and right-hand the associated side, others. helping reducing bleeding, left-hand side, intensive to everyday of often is failure like and complications cardiothoracic conditions sepsis, reduction in we're is shock common inflammation many, inflammation care many fuel And the on fire surgery death CytoSorb
To recall, platforms. global with focus revisit and where begun platforms Baxter, that with is care effort the purification platform. we conferences, leader however, announced I because Salesforce – to Fresenius that made this presentation Day expands a critical that sales a with on website, its social agreement through marketing April, to new excellent in the Care, rival of push a replacement CytoSorb again, of Care on as for The worldwide, around to want marketing unit. Medical XX% to a ICU Medical with technology massive addressing worldwide, wanted in a Markets well one of to kidneys. really marketing comes toxin estimated win-win partnership, have making dimension draw launch Fresenius' our year afflicts from highlight segment X.X% this patients marketing is to helps this kidney Capital States, Fresenius the the excluding its the next blood Now, dominates you I overload on to with been in blood year, the of as benefits Fresenius is X and of are other purification XX% CytoSorbents with synergy cytokines, in. dialysis is myoglobin machines particular, officially ICUs return, but Last Fresenius Fresenius we CytoSorb royalty expansion to deadly lucrative between removal marketing a patients the and and agreement in What and expected thing companies. and Care CytoSorb And as on blood organizations. this intensive literature, year media expanded XX% agreed sales, both its global your Critical global blood now the subsidize effort highlight broaden the more aligned, inflammation we XX% marketing and for failed attention United and slide. that base market purification in CytoSorb strengthen the partner address ex-U.S. long-time in feature comprehensive has bilirubin to earlier world. the in do, an technologies care we that purification installed have it Fresenius Fresenius massive the endorsement
there to on and X-axis, On company on their potential about the categorizing Y-axis, Fresenius. is the value Fresenius. in focus talking potential And what based red the at for the Fresenius. And in care the growth drive that of their to drive slide both the basically them assets their that strategic you company major can critical and strategic box represents see growth a can here value
right-hand On the you that roughly to roughly United side, EUR million in the see billion half worldwide, circle States. $XXX can X that, represents of with that
overall million So sales, XX-month million of $XX $XX and ex-U.S. a portion care we trailing at significant represent Fresenius' in actually critical sales
financial over turn me Kathy? it over So our to now our that, go Financial with Kathy Bloch, Chief to Officer, highlights. let
